Habtezion Aida has officially reported ownership in Azora Therapeutics, Inc. through a recent filing. This Form 3, submitted on November 10, 2026, signifies Aida's role as a director at Azora. The filing is essential as it reflects Aida's commitment to the company and the ongoing evolution within the pharmaceutical preparations sector.

Azora Therapeutics, Inc., a company incorporated in Delaware, operates within the pharmaceutical preparations industry, specifically categorized under SIC 2834. The company has undergone several name changes in the past, previously known as Adial Pharmaceuticals, Inc. and Adial Pharmaceuticals, L.L.C. The most recent filing indicates that Azora is actively navigating its corporate governance and ownership structure.

The filing states that Aida is a director at Azora Therapeutics. It also notes that Aida holds one security, which highlights a direct interest in the company. The Form 3 filing serves to disclose the ownership stake and any changes in ownership, ensuring transparency in corporate governance. Aida's signature was provided by Matthew Davidson, acting as attorney-in-fact.

This development may impact various stakeholders, including investors, employees, and competitors within the pharmaceutical industry. Aida's involvement as a director could guide strategic decisions and influence the company's future direction. The filing is a part of the ongoing regulatory requirements for those in significant positions within publicly traded companies.

The filing does not specify what actions will follow this ownership report. However, it is clear that Aida's role will be pivotal in shaping the company's strategies moving forward.